Phase II, randomized, double-blinded, placebo-controlled multicenter study of Selinexor KPT-330 Carlf, and Dexa, in R/R MM pts who previously have been treated with proteasome inhibitor and an immunomodulatory drug
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Karyopharm Therapeutics
Start Date
March 15, 2016
End Date
October 14, 2017
Administered By
Duke Cancer Institute
Awarded By
Karyopharm Therapeutics
Start Date
March 15, 2016
End Date
October 14, 2017